A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia

Haematologica

Volumn 94, Issue 3, 2009, Pages 433-435

  Iwanaga, Eisaku ^a   Nanri, Tomoko ^a   Matsuno, Naofumi ^a   Kawakita, Toshiro ^a   Mitsuya, Hiroaki ^a   Asou, Norio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Acute myeloid leukemia; FLT3, t(8; 21); JAK2; KIT

Indexed keywords

FLT3 LIGAND; JANUS KINASE 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PATIENT; CHROMOSOME 21Q; CHROMOSOME 8Q; CHROMOSOME TRANSLOCATION; GENE MUTATION; HUMAN; LETTER; ONCOGENE K RAS; ONCOGENE N RAS;

ACUTE DISEASE; ADULT; AGED; AMINO ACID SUBSTITUTION; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; JANUS KINASE 2; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID; MALE; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; TRANSLOCATION, GENETIC;

EID: 62949216348     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.13283     Document Type: Letter

References (12)

1. Asou N. The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. Crit Rev Oncol Hematol 2003;45:129-50.
2. Kuchenbauer F, Schnittger S, Look T, Gilliland G, Tenen D, Haferlach T, et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol 2006; 134:616-9.
3. Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21) (q22;q22). Leukemia 2005;19:1361-6.
4. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:3463-8.
5. Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007;17:8-14.
6. Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25:1434-6.
7. Döhner K, Du J, Corbacioglu A, Scholl C, Schlenk RF, Döhner H. JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. Haematologica 2006;91:1569-70.
8. Illmer T, Schaich M, Ehninger G, Thiede C. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. Haematologica 2007;92:137-8.
9. Vicente C, Vázquez I, Marcotegui N, Conchillo A, Carranza C, Rivell G, et al. JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers. Leukemia 2007;21:2386-90.
10. Schnittger S, Bacher U, Kern W, Haferlach C, Haferlach T. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML. Leukemia 2007;21:183-4.
11. Heller PG, Lev PR Salim JP, Kornblihtt LI, Goette NP, Chazarreta CD, et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 2006;77:210-6.
12. Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer 2005;104:2726-34.